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Abstract
We conﬁrmed the performance of an array method for plasma epidermal growth factor receptor (EGFR)
mutation detection and showed the association of plasma EGFR mutation with survival outcomes.
Background: Noninvasive detection of epidermal growth factor receptor (EGFR) mutation in plasma is feasible and
could be adjunct for therapeutic monitoring especially when repeated biopsy of tumor tissue is challenging. The aims
of this study were to establish the diagnostic performance of peptide nucleic acid-locked nucleic acid polymerase
chain reaction followed by custom array for plasma EGFR mutation and to evaluate the association of detection with
clinical characteristics and survival outcomes. Materials and Methods: Plasma genomic DNA from consecutive
advanced lung cancer subjects was tested for EGFR mutations before anticancer treatment, and compared with
mutation status in tumor tissue. Clinical characteristics were compared between patients who were EGFR-mutant and
wild type; and within EGFRmutants, whether EGFRmutations could be detected in plasma. Results: In 74 lung cancer
patients, the sensitivity, speciﬁcity, and positive and negative predictive values of plasma EGFR detection were
79.1%, 96.8%, 97.1%, and 76.9%, respectively. EGFR mutants with concomitant detection of plasma EGFRmutation
showed worse survival compared with mutants with no concomitant plasma mutation detected in biopsy specimens.
Conclusion: Plasma EGFRmutation detected using this method demonstrated high diagnostic performance. In EGFR
mutants, plasma EGFR mutation detection correlated not only EGFR mutation status in biopsy but was also asso-
ciated with worse prognosis compared with EGFR mutant without plasma EGFR mutation detection.
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The detection of epidermal growth factor receptor (EGFR) muta-
tions in tissue biopsy has become a routine molecular test with diag-
nostic and therapeutic implications for advanced stage nonesmall-cell
lung cancer (NSCLC). The presence of activating EGFR mutations,
namely exon 19 deletion or L858R mutation at exon 21, predicts
favorable response to the EGFR tyrosine kinase inhibitors (TKIs).1 In
clinical situations in which patients are not medically ﬁt for invasiveDepartment of Medicine, University of Hong Kong, Hong Kong SAR, China
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sible to repeat a biopsy. Even if repeat biopsy is possible, the amount of
tissue obtained could either be inadequate for molecular testing
because of its small quantity or very low tumor content or is not readily
available.
Plasma DNA might provide a noninvasive means of detecting
plasma EGFR mutations. Several different methods, including high
performance liquid chromatography,2 allele-speciﬁc polymerase
chain reaction (PCR) with Scorpion-ampliﬁcation3,4 or subsequent
sequencing,5 peptide nucleic acid (PNA)-mediated PCR clamping
methods,6mass spectrophotometry genotyping,7 BEAMing,8 and the
droplet digital PCR,9,10 and next-generation sequencing11 have been
established and reported for the detection of EGFR mutations in
DNA isolated from plasma2,10,12 with variable but comparable per-
formance13 and showed some correlation between mutation status inClinical Lung Cancer November 2015 - 507
Table 1 A List of the PCR Primers Used for Ampliﬁcation of
EGFR Exon 19 and 21 in Plasma DNA
For First Round Ampliﬁcation from Genomic DNA Templates
Exon 19 (50>30 )
Forward: CCAGATCACTGGGCAGCATGTGGCACC
Reverse: AGCAGGGTCTAGAGCAGAGCAGCTGCC
Exon 21 (50>30 )
Forward: TCAGAGCCTGGCATGAACATGACCCTG
Reverse: GGTCCCTGGTGTCAGGAAAATGCTGG
For Second Round Seminested Ampliﬁcation
on PCR Amplicons from First Round PCR
Exon 19 Reverse nested
TGGACCCCCACACAGC
Exon 21 Reverse nested
TGCCTCCTTCTGCATGGTATTC
Abbreviation: PCR ¼ polymerase chain reaction.
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508 -plasma, pleural ﬂuid, and tumor tissue.14 Furthermore, EGFR mu-
tations detected in plasma or serum might, by itself, be predictive of
response to EGFRTKIs.2,12,14 All of these reports described detection
sensitivity from 66% to 100% and a speciﬁcity from 63% to 100%.
We reported previously, using the same method as in this study,
the successful detection of EGFR mutation in plasma DNA
extracted from patients with advanced-stage NSCLC.15 The aim of
this study was to establish the performance of the PNA-locked
nucleic acid (LNA) PCR followed by speciﬁc custom array hy-
bridization in the detection of EGFR mutations in plasma samples
of patients with advanced stage NSCLC and to study for any
prognostication or association between plasma EGFR mutation
detection, clinical characteristics, and survival outcomes.
Materials and Methods
Lung Cancer Patients
We recruited patients with newly diagnosed biopsy or cytology-
proven stage III or IV NSCLC under medical care in the Depart-
ment of Medicine, QueenMary Hospital, University of Hong Kong.
Patients with small-cell lung cancer, with Eastern Cooperative
Oncology Group (ECOG) performance status 3, or who could not
give informed consent were excluded from recruitment. The study
was approved by the University of Hong Kong/Hong Kong Hospital
Authority Institutional Review Board and Ethics Committee (HKU/
HA HKW IRB UW 13-488). Tumor biopsy samples were analyzed
with routine histopathological and molecular pathology service on
formalin-ﬁxed, parafﬁn-embedded specimens. Recruited patients
were followed-up for their subsequent management for treatment
response, disease control and progression, lines of treatment, and
duration of progression-free survival (PFS) and overall survival (OS).
Venous blood samples (10 mL) were collected from all recruited
subjects before they were started on any and on the same day of
starting anticancer therapy. The choice of treatment was reached by
attending physicians and patients without knowing the plasma status
of EGFR mutation. At recruitment, subject demographic charac-
teristics were recorded. The recruited subjects were followed-up with
usual clinical care at every subsequent 3-4 weeks. Chest x-ray was
performed at every visit to check for obvious clinical progression and
detail imaging with computed tomography (CT) or positron emis-
sion tomography-CT was done only when clinical progression was in
doubt. PFS was taken as the duration from the commencement of
ﬁrst-line anticancer therapy to the day with clinical disease progres-
sion noted on chest imaging or physical examination that showed
new sites of involvement like regional lymph node enlargement. OS
was taken from the commencement of ﬁrst-line anticancer therapy to
either the day of death or last clinic follow-up. Four recruited subjects
(in the EGFR wild type group) who had never received any anti-
cancer treatment were not counted for PFS, but their OS was taken
as the duration from the day of venous sampling for this study until
the day of death or last clinical follow-up. All patients had been
informed that EGFR TKIs are known to be less effective in EGFR
wild type tumors compared with EGFR mutant tumors, and the
ultimate choice of therapy was decided by the patient. All clinical
information were not disclosed to the research laboratory staff
responsible for plasma EGFR mutation assay.
Blood samples were collected in citrated tubes, and centrifuged at
1800g for 10 minutes to separate the plasma. Aliquots of plasmaClinical Lung Cancer November 2015were immediately subjected to DNA extraction (Qiagen DNA
mini-kit, Hilden, Germany) and the plasma DNA thus extracted
was stored at 80C until usage for PCR ampliﬁcation.
Epidermal Growth Factor Receptor Exon 19 Deletion and
Exon 21 L858R Assay in Plasma
Detection of the deletions in exon 19 and L858Rmutation in exon
21 of EGFR was performed using the PNA-LNA PCR clampmethod
followed by array hybridization with allele-speciﬁc arrayed primer
extension as previously described.15 The primer sequences are listed in
Table 1. Tests were performed at least twice for every sample.
Statistical Analyses
The relationships between EGFR mutation and factors such as sex,
age, tumor, node, metastases (TNM) stage, histologic type, smoking,
PFS, and OS were examined using the Student t test, c2 test, or Fisher
exact test where appropriate, and KaplaneMeier analysis using PASW
software (IBM, Armonk, NY) version 19. Mean and SD were used for
continuous variables in normal distribution and median and inter-
quartile ranges were used for PFS and OS. Data not in normal distri-
bution were logarithmic-transformed before parametric tests. Pearson
and Spearman correlations were applied to tests for the correlations
between clinical parameters of age, sex, smoking status, TNM staging,
ECOG performance status, tumor biopsy EGFR mutation status,
plasma EGFR mutation, plasma detected and not detected among tu-
mor biopsy EGFR mutant samples. Stepwise multiple regression
models were built to determine the clinical parameters that indepen-
dently predicted either PFS or OS. Cox regression and KaplaneMeier
analyses were used to compare cumulative survival between different
groups. All P values were 2-sided and P < .05 was considered
statistically signiﬁcant. The prevalence, sensitivity, speciﬁcity, and
positive and negative predictive values of EGFR detection were
calculated using the free Web statistical tools: www.vassarstats.net.
Results
Patients and Tumor Characteristics
Of 102 consecutive subjects admitted for management of newly
diagnosed advanced-stage NSCLC, 83 patients met all inclusion
David C.L. Lam et alcriteria and 11 small-cell lung cancer patients, 5 with poor perfor-
mance status (ECOG performance status > 3), and 3 patients
mentally incompetent to give consent were excluded. Eight recruited
subjects were found to have inadequate tumor biopsy tissue for
EGFR mutation analysis (4 of them had either squamous-cell car-
cinoma or large-cell carcinoma that showed necrotic tumor tissue and
quality was deemed not suitable for EGFR mutation analysis) and 1
patient sample was excluded because of technical problems. Finally,
74 patients with advanced-stage lung cancer were eligible. Patient
characteristics are summarized in Table 2. There were 38 men and 36
women, 72 lung adenocarcinomas (97%), 25 smokers (former or
current smokers; 34%), and 49 were never-smokers (66%). Twenty-
four tumors (32%) had EGFR exon 19 deletion (15-base pair dele-
tion in 27 cases), and 19 tumors (26%) had the EGFR L858R
mutation. The remaining 31 patients (42%) were EGFR wild type
(Table 3). Of 43 EGFR-mutant patients, 42 received EGFR TKIs
and 15 of 31 EGFR wild type subjects received chemotherapy as ﬁrst-
line treatment, and the remaining 4 of 31 patients opted for no
anticancer treatment and 12 of 31 opted for EGFR TKI treatment
(Table 3). All patients had been informed that EGFR TKIs are
known to be less effective in EGFR wild type tumors compared with
EGFR-mutant tumors, and the ultimate choice of therapy was
decided by the patient. Among biopsy EGFR-mutant (n ¼ 43), 33
(77%) had plasma EGFR mutation detected and 10 (23%) did
not have plasma EGFR mutation detected (Table 4).Table 2 Summary of Clinical Characteristics of All Recruited
Subjects
Characteristic Value
Total Recruited, n 74
Age, Years 64.54  11.96
Sex
M:F ratio 1:1
M 38 (51%)
F 36 (49%)
Smoking History
SM:NS ratio 1:2
Ever-smoker 25 (34%)
NS 49 (66%)
Histology
AD 72 (97%)
NSCLC-NOS 1 (1%)
SCC 1 (1%)
Stage
IIIA 2 (3%)
IIIB 2 (3%)
IV 70 (95%)
M1a 31 (42%)
M1b 39 (53%)
Median PFS (Range), Days 193 (82-374)
Median OS (Range), Days 347 (193-537)
Abbreviations: AD ¼ adenocarcinoma; F ¼ female; M ¼ male; NOS ¼ not otherwise speciﬁed;
NS ¼ nonsmoker; NSCLC ¼ nonesmall-cell lung cancer; OS ¼ overall survival;
PFS ¼ progression-free survival; SCC ¼ squamous cell carcinoma; SM ¼ smoker.Diagnostic Performance of the PNA-LNA Method
Followed by Array Hybridization
The prevalence of biopsy EGFR mutations was 58.1% (43 of 74;
95% conﬁdence interval [CI], 46.1%-69.3%) and 34 of 43 EGFR
mutant were identiﬁed from plasma (true positive), 30 of 31 EGFR
wild type were conﬁrmed from plasma (true negative; Table 5). The
sensitivity of plasma EGFR detection was 79.1% (95% CI,
63.5%-89.4%) and speciﬁcity was 96.7% (95% CI, 81.5%-99.8%),
with a positive predictive value of 97.1% (95% CI, 83.4%-99.9%)
and a negative predictive value of 76.9% (95% CI, 60.3%-88.3%;
Table 5).
Survival Analysis
Cox regression analysis showed signiﬁcant correlations between
TNM staging (stage III, IV M1a, IV M1b) and log PFS
(r ¼ 0.253; P ¼ .03) and between plasma mutation detection and
log OS (r ¼ 0.324; P ¼ .034), and no correlation was found be-
tween TNM staging and plasma mutation detection (r ¼ 0.199;
P ¼ .201). There were no signiﬁcant correlations between different
clinical parameters and PFS or OS in correlation matrix analysis.
For the biopsy EGFR-mutant patients, the median PFS for those
with plasma mutation detected was shorter than for those without
plasma mutation detected but the difference was not statistically sig-
niﬁcant (P¼ .052) and themedianOS for those with plasmamutation
detected was signiﬁcantly shorter than for those without plasma mu-
tation detected (P¼ .028; Table 4). KaplaneMeier analysis, however,
conﬁrmed signiﬁcantly better PFS and OS in biopsy EGFR-mutant
compared with biopsy EGFR wild type subjects (Figure 1A [PFS],
P ¼ .02, and Figure 1B [OS], P ¼ .04); and among biopsy EGFR
mutants, a signiﬁcantly worse PFS andOS in those with plasma EGFR
mutation detected than for those with no plasma EGFR mutation
detection (Figure 1C [PFS], P¼ .028, and Figure 1D [OS], P¼ .038).Discussion
In the present study, we found that this method of EGFRmutation
detection in plasma DNA samples showed high concordance with
tumor genotyping in 86% of the cases (64 of 74; Table 5). In plasma
DNA, we detected 79% (19 of 24) of EGFR exon 19 deletion cases,
and 74% (14 of 19) of EGFR L858R mutation cases, compared with
the matched primary tumors. Depending on the technique, the
concordance betweenEGFR status in tumor and plasma and/or serum
samples varied from 66% to 100%, with the highest correlation being
found recently in digital droplet PCR.2,4,5,9,10,12,14,16 The overall
diagnostic sensitivity and speciﬁcity of 79.1% and 96.8%, respec-
tively, should make it a useful test for subsequent monitoring along the
treatment course, especially when repeat biopsy is not always feasible.
The high positive predictive value (97.1%) and true negative predictive
value (76.9%) indicated the high diagnostic performance of this test and
were comparable with other tests reported in the literature.2,12,17 How-
ever, the application and usefulness of plasma EGFRmutation detection
in longitudinal follow-up warrants further larger scale prospective study,
especially when plasma EGFRmutations could be assessed repeatedly at
different time points of treatment or disease progression much more
readily than repeat of tissue biopsies for EGFRmutation status.
There was 1 false positive result from a 75-year-old man with
stage IV adenocarcinoma of the lung with contralateral lungClinical Lung Cancer November 2015 - 509
Table 3 Characteristics of EGFR Mutant Subjects Compared
With EGFR Wild Type Subjects
Characteristic
EGFR
Mutant
EGFR
Wild Type P
Total, n 43 31
Age, Years 66.72  9.145 61.52  4.651 .064
Sex
M:F ratio 1:1.6 1:0.5 .017a
M 17 (40%) 21 (68%)
F 26 (60%) 10 (32%)
Smoking History
SM:NS 1:4.4 1:0.9 .001a
Ever-smoker 8 (19%) 17 (55%)
NS 35 (81%) 14 (45%)
Histology
AD 41 (96%) 31 (100%) .506 (NSCLC and
SCC combined)
NSCLC 1 (2%) 0 (0%)
SCC 1 (2%) 0 (0%)
Stage
IIIA 2 (4%) 0 (0%)
IIIB 0 (0%) 2 (6%)
IV 41 (96%) 29 (94%) .572
M1a 17 (41%) 14 (49%)
Contralateral lung 6 8
Pl effusion 11 6
M1b 24 (59%) 15 (51%)
Intra-abdominal 0 2
Adrenal 4 0
Bone 19 11
Brain 1 2
ECOG PS
0 21 (49%) 12 (39%) .554
1 20 (47%) 16 (52%)
2 2 (5%) 3 (10%)
Treatment
First line
No treatment 0 (0%) 4 (14%)
Geﬁtinib 33 (77%) 6 (19%)
Erlotinib 9 (21%) 6 (19%)
Chemotherapy 1 (2%) 15 (48%)
Second line
No treatment 21 (49%) 22 (71%)
Geﬁtinib 2 (4%) 2 (6%)
Erlotinib 7 (17%) 2 (6%)
Chemotherapy 13 (30%) 5 (17%)
Third line
No treatment 31 (72%) 24 (77%)
Geﬁtinib 0 (0%) 0 (0%)
Erlotinib 2 (5%) 1 (3%)
Chemotherapy 10 (23%) 6 (20%)
Table 3 Continued
Characteristic
EGFR
Mutant
EGFR
Wild Type P
Median PFS
(Range), Days
239 (151-408) 104 (46-258) .001a
Median OS
(Range), Days
371 (239-580) 336 (84-483) .017a
Abbreviations: AD ¼ adenocarcinoma; ECOG PS ¼ Eastern Cooperative Oncology Group
performance status; F ¼ female; M ¼ male; NS ¼ nonsmoker; NSCLC ¼ nonesmall-cell lung
cancer; OS ¼ overall survival; PFS ¼ progression-free survival; SCC ¼ squamous cell car-
cinoma; SM ¼ smoker.
aP < .05.
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510 - Clinical Lung Cancer November 2015nodules. He presented with superior vena cava obstruction and
received local radiation therapy. He quickly deteriorated with
development of sepsis and pneumonia and died 2 weeks after
radiotherapy. His tumor biopsy sample had tested as EGFR wild
type but the plasma samples had tested as L858R present. Unfor-
tunately, the patient died shortly after radiotherapy and would not
allow the time for further monitoring of plasma EGFR status. We
can only hypothesize that this discrepancy between tested tumor
biopsy and tested plasma could be a real false positive result or it
might indeed reﬂect heterogeneity of the tumor. Similar discordance
has been reported occasionally when other plasma detection
methods were used.7,18
We attempted to prove the false negative results with repeat
testing and conﬁrmed negative results in the plasma for biopsy
EGFR wild type tumors. Negative results for plasma tests probably
reﬂect no or undetectable tumor DNA leakage into the systemic
circulation, especially when a tumor is relatively nonactive or not
inﬂamed. Among the known EGFR mutants from tumor biopsy, we
compared the plasma-detected cases with plasma nondetected cases
and KaplaneMeier analysis showed signiﬁcantly better PFS and OS
for plasma nondetected cases (Figure 1). Unlike most other reports
for plasma EGFR mutation detection,2,5,7,10 all of the subjects in
this study were prospectively recruited, and the corresponding
plasma samples were collected, before the subjects received any
anticancer therapy. Thus, any plasma detection might be an indirect
reﬂection of the tumor load or activity before treatment, such that
those tumors with active replication were leaking DNA into the
systemic circulation and thus conferring a worse prognosis for the
respective subjects compared with those with no leakage of tumor
DNA into the systemic circulation.19 Similar survival beneﬁts have
been observed in subanalyses of a previous Iressa Pan-Asia Study
cohort in which subjects with no EGFR mutation detected in serum
appeared to fare better in terms of PFS and overall response rate
after treatment, compared with EGFR-mutant subjects with EGFR
mutation detected in serum.20 It is possible that the better survival
observed in biopsy EGFR-mutant patients without concomitant
plasma EGFR mutation detected could reﬂect a lower or less active
tumor load or disease with lesser leakage of tumor DNA into the
systemic circulation, but this remains to be explored in future
prospective larger scale randomized studies.
Kim et al reported a very low detection rate (16.7%) in a cohort
of 60 patients with pair pretreatment and 2-months posttreatment
Table 4 Comparison of Biopsy EGFR Mutant With Plasma
Mutation Detection Versus Those With EGFR Mutation
in Biopsy but Not Detected in Plasma
Characteristic
Biopsy EGFR Mutant (n [ 43)
P
Plasma
Mutation
Detected
Mutation Not
Detected in
Plasma
Total 33 10
Age, Years 66.82  8.766 66.4  10.814 .901
Sex
M:F 1:1.6 1:1.5 1
M 13 (39%) 4 (40%)
F 20 (61%) 6 (60%)
Smoking History
SM:NS 1:5.6 1:2.4 .362
Ever-smoker 5 (15%) 3 (30%)
NS 28 (85%) 7 (70%)
Histology
AD 31 (94%) 10 (100%)
NSCLC 1 (3%) 0 (0%)
SCC 1 (3%) 0 (0%)
Stage
IIIA 1 (3%) 1 (10%)
IIIB 0 (0%) 0 (0%)
IV 32 (97%) 9 (90%) .45
M1a 12 (38%) 5 (56%)
Contralateral lung 2 4
Pl effusion 10 1
M1b 20 (63%) 4 (44%)
Intra-abdominal 0 0
Adrenal 4 0
Bone 15 4
Brain 1 0
ECOG PS
0 17 (52%) 4 (40%) .322
1 14 (42%) 6 (60%)
2 2 (6%) 0 (0%)
Treatment
First line
No treatment 0 (0%) 0 (0%)
Geﬁtinib 27 (82%) 6 (60%)
Erlotinib 6 (18%) 3 (30%)
Chemotherapy 0 (0%) 1 (10%)
Second line
No treatment 16 (48%) 5 (50%)
Geﬁtinib 2 (6%) 0 (0%)
Erlotinib 6 (18%) 1 (10%)
Chemotherapy 9 (27%) 4 (40%)
Third line
No treatment 25 (76%) 6 (60%)
Geﬁtinib 0 (0%) 0 (0%)
Erlotinib 1 (3%) 1 (10%)
Chemotherapy 7 (21%) 3 (30%)
Table 4 Continued
Characteristic
Biopsy EGFR Mutant (n [ 43)
P
Plasma
Mutation
Detected
Mutation Not
Detected in
Plasma
Median PFS
(Range), Days
239 (146-368) 420 (233-676) .051
Median OS
(Range), Days
305 (211-512) 572 (346-737) .028a
Abbreviations: AD ¼ adenocarcinoma; ECOG PS ¼ Eastern Cooperative Oncology Group
performance status; F ¼ female; M ¼ male; NS ¼ nonsmoker; NSCLC ¼ nonesmall-cell lung
cancer; OS ¼ overall survival; PFS ¼ progression-free survival; SCC ¼ squamous cell car-
cinoma; SM ¼ smoker.
aP < .05.
David C.L. Lam et alsamples, using a similar PNA-LNA PCR method.6 Although we had
a similar experience of poor detection rate when we developed this
plasma EGFR detection method previously,15 the detection rate
markedly improved with fresh processing of collected blood
specimens without refrigeration, and citrated blood samples
were found to be much better than blood collected with ethyl-
enediaminetetraacetic acid container tubes.6
Our study sample showed a signiﬁcant imbalance between group
distributions (ie, signiﬁcantly more female nonsmokers in the
EGFR-mutant group; Table 3), but this also reﬂected the real life
setting of gender and smoking status distribution in the local and
most other populations1 and should not have severely confounded
the comparison with other similar studies in the literature.2,6,7,9,12,16
The regression analysis in this study also showed that TNM staging
and plasma EGFR mutation detection were the predictors for OS
independent of the potential confounding effects of age, sex,
smoking status, performance status, and lines of treatment. We did
not assess the degree of tumor necrosis or inﬂammation and tumorTable 5 The Rate of EGFR Mutations Detected in Plasma and
Biopsy Samples; and Diagnostic Sensitivity and
Speciﬁcity, and Positive and Negative Predictive
Values of This Method of EGFR Detection in Plasma
Rate of EGFR Mutations Detected in Plasma and Biopsy Samples
Biopsy EGFR
Wild Type
Biopsy EGFR
Mutant Total
Plasma EGFR
Mutant
1 34 35
Plasma EGFR
Wild Type
30 9 39
Total 31 43 74
Diagnostic Sensitivity and Speciﬁcity, and Positive and Negative
Predictive Values of This Method of EGFR Detection in Plasma
Estimated
Value (%)
95% CI
Lower Limit Upper Limit
Sensitivity 79.1 63.5 89.4
Speciﬁcity 96.8 81.5 99.8
Positive
Predictive Value
97.1 83.4 99.9
Negative
Predictive Value
76.9 60.3 88.2
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Figure 1 Survival Analysis for (A) PFS and (B) OS for Biopsy EGFR-Mutant Versus Wild Type Subjects; (C) PFS and (D) OS for Biopsy
EGFR-Mutant Subject With Plasma EGFR Mutation Detected Versus Plasma EGFR Mutation Not Detected
The * Indicates the Statistical Signiﬁcance of P Value.
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512 -heterogeneity, factors which might affect the plasma mutation
status.18
The ﬁndings of this study have raised a few interesting issues that
warrant further research. In this study, all recruited patients were
advanced-stage disease subjects and further studies in early-stage lung
cancer subjects are needed to evaluate the possibility of such plasma
EGFR mutation detection in early-stage disease. Future studies with
longitudinal follow-up and serial testing would allow exploration of
the clinical usefulness of qualitative and quantitative monitoring of
plasma EGFRmutation status in advanced-stage lung cancer subjects
who receive EGFR-targeted therapy. Finally, it is important to note
that, although we and others have demonstrated that the molecular
diagnosis of EGFR status based on plasma DNA samples is feasible,
analysis for EGFR mutations in tumor DNA remains the gold
standard for diagnosis of EGFR mutation status of lung cancer.Clinical Lung Cancer November 2015Conclusion
The detection method used in this study of EGFR mutation at
exon 19 deletions and exon 21 L858R mutations in plasma DNA
samples from patients with lung cancer is a reliable, technically
feasible method with high diagnostic performance. The better sur-
vival observed in biopsy EGFR-mutant without concomitant plasma
EGFR mutation detected could reﬂect a lower or less active tumor
load or disease with lesser leakage of tumor DNA into the systemic
circulation, but this remains to be validated in future prospective
larger-scale randomized studies.Clinical Practice Points
 Plasma EGFR mutation is detectable in advanced-stage lung
cancer patients.
David C.L. Lam et al Plasma EGFR mutation detection is not only feasible but the
detection of EGFR mutation in plasma is also associated with
survival outcomes.
 The detection of EGFR mutation in plasma could be of prog-
nostic signiﬁcance in advanced-stage lung cancer patients.Acknowledgments
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